Herbert Towning was appointed Chairman in 2013 and brings more than 40 years of banking experience to the role. Educated at Nottingham University and a postgraduate of the London School of Economics, Herbert started his career with CT Bowering & Co. before progressing through various banking houses in London. In 1974, he left the UK to commence an international banking career in Europe, the United States, the Bahamas and the Arabian Gulf with the International Investment Corporation Bahrain until 1994, after which time he took corporate retirement. He then became a partner in Establissement Pour le Placement Prive in Liechtenstein, Switzerland and London.
Herbert is a private equity investor in both Europe and the United States and has acted as a consultant to a number of successful public companies assisting in the raising of investment capital and working in corporate communications, business development and investor relations.
He is a director of Intercept Energy Services Inc (symbol TSX-V – IES) of Calgary, Alberta. as well as OWaste2Energy Company Ltd. in Vancouver, British Columbia and R3 Medio Ambiente de Mexico SAPI de CV in Mexico.
Guy joined Zephyrus as CEO in 2018. With over 10 years’ experience in the medical device and medical services sector, Guy was previously CEO of Leaders in Oncology Care, a subsidiary of HCA International, the largest private healthcare provider in the world looking after the entire cancer network. Guy is currently Chairman of Perci Health, a private telehealth services Company, with a pioneering virtual care clinic designed to support people living with cancer as well as employees impacted by cancer.
Guy studied Law at Oxford University and qualified as a solicitor with Linklaters in 2015. Guy spent several years at Credit Suisse in Equity Corporate Finance Team.
Will joined Zephyrus as COO in 2020. Prior to this, Will was CEO of a direct-to-consumer business, The London Sock Company.
Will began his career as a management consultant for Accenture where he advised a number of clients on Technology Transfer Programmes. Over the course of his career, Will has held a number of Senior roles focussing on strategy, estimation, planning and delivery with a wide variety of clients including Deutsche Bank, BBC, Thales, and BT.
Will studied Natural Sciences at Bath University and went on to study law at University of London.
David is a successful medical device engineer with over twenty years’ of experience. He has been involved in the development of the first fully portable PCR and the first PCR-based point-of-care test for the infectious diseases chlamydia and gonorrhea to gain US FDA clearance.
David has also worked on the development and scale-up of a range of other medical and drug delivery devices in the UK and Europe. He has a First Class Medical Engineering degree.